Clinical efficacy of highly purified hMG versus recombinant FSH in IVF/ICSI cycles: a meta-analysis.
OBJECTIVE
To compare the effectiveness of highly purified hMG (Menopur) with recombinant FSH (Gonal-F) in IVF/ICSI patients who underwent ovarian hyperstimulation with pituitary suppression.


METHODS
A literature search of the National Library of Medicine and the National Institutes of Health (PubMed), Medline and Cochrane Controlled Trials Register was performed using the key words 'highly purified hMG' and 'recombinant FSH.' Only prospective randomized controlled trials were included when they compared IVF/ICSI outcomes after administration of Menopur versus Gonal-F. Five studies met the inclusion criteria and were reviewed. The primary outcome measure was ongoing pregnancy/live birth.


RESULTS
Ongoing pregnancy rate per started cycle (RR: 1.10, 95% CI: 0.96-1.26) or per embryo transfer (RR: 1.13, 95% CI: 0.99-1.29), as well as live birth rate per embryo transfer (RR: 1.14, 95% CI: 0.98-1.33), is similar between the Menopur and the Gonal-F group.


CONCLUSIONS
The combined data presented in this meta-analysis do not support a clinical superiority of Gonal-F over Menopur.
Jee
Byung Chul
BC
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
Suh
Chang Suk
CS
Kim
Yong Beom
YB
Kim
Seok Hyun
SH
Moon
Shin Yong
SY
D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D006801:Humans; D008596:Menotropins / Q000627:therapeutic use*; D011247:Pregnancy; D018873:Pregnancy Rate; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011994:Recombinant Proteins / Q000627:therapeutic use; D020554:Sperm Injections, Intracytoplasmic / Q000379:methods*
D005300:Fertility Agents, Female; D011994:Recombinant Proteins; D008596:Menotropins; D005640:Follicle Stimulating Hormone